CLINICAL TRIAL: A PHASE III DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL OF LONG TERM

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是测试长期口服抗病毒治疗是否改善了标准IV抗病毒治疗后单纯疱疹病毒性脑炎(HSE)的长期结果。正在研究的具体问题包括： 1-长期口服万乃洛韦能改善HSE的预后吗？ 当长期服用万乃洛韦治疗HSE时，人体如何吸收、代谢和消除大剂量的万乃洛韦？ HSE后的神经学结果与中枢神经系统中单纯疱疹病毒的数量之间有关系吗？

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Purpose of this study is to test whether prolonged oral antiviral therapy improves long term outcome of herpes simplex encephalitis [HSE] following standard IV antiviral treatment. Specific questions being looked at are: 1- Does long term oral valacyclovir improve outcomes in HSE? 2- How does the body absorb, metabolize, and eliminate high dose oral valacyclovir when used long term for HSE? 3- Is there a relationship between neurologic outcomes following HSE and the amount of Herpes Simplex virus in the Central Nervous System?